Kronos Bio, Inc. (KRON)
NASDAQ: KRON · IEX Real-Time Price · USD
1.020
+0.038 (3.89%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.
Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dr. Norbert W. Bischofberger Ph.D. |
Contact Details
Address: 1300 S. El Camino Real, Suite 400 San Mateo, California 94402 United States | |
| Phone | (650) 781-5200 |
| Website | kronosbio.com |
Stock Details
| Ticker Symbol | KRON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001741830 |
| CUSIP Number | 50107A104 |
| ISIN Number | US50107A1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Norbert W. Bischofberger Ph.D. | President, Chief Executive Officer and Director |
| Joshua A. Kazam | Co-Founder and Director |
| Sandra A. Gardiner | Interim Chief Financial Officer and Principal Accounting Officer |
| Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development and Investor Relations |
| Allison Frisbee J.D. | Senior Vice President of Corporate Operations and Legal |
| Dr. Charles Lin Ph.D. | Senior Vice President of Research and Development |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development |
| Wes Trotter Ph.D. | Senior Vice President of Drug Discovery and Pharmaceutical Development |
| Rocio Martin Hoyos | Senior Vice President of Corporate Strategy and Portfolio Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |